Icade SA
PAR:ICAD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Icade SA
PAR:ICAD
|
FR |
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
UK |
|
Resorttrust Inc
TSE:4681
|
JP |
|
C
|
Credit Suisse Group AG
XHAM:CSX
|
CH |
|
H
|
HIVE Blockchain Technologies Ltd
NASDAQ:HIVE
|
CA |
|
Paragon REIT
F:50E
|
SG |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
US |
|
B
|
BPH Energy Ltd
ASX:BPH
|
AU |
|
O
|
Open Text Corp
SWB:OTX
|
CA |
|
I
|
Itmax System Bhd
KLSE:ITMAX
|
MY |
|
Vertex Inc
NASDAQ:VERX
|
US |
|
Compagnie De l'odet SE
PAR:ODET
|
FR |
|
F
|
First Tractor Co Ltd
OTC:FIRRY
|
CN |
|
Z
|
Zen Corporation Group PCL
SET:ZEN
|
TH |
|
G
|
Guangdong Investment Ltd
F:GUG
|
HK |
Wall St Price Targets
ICAD Price Targets Summary
Icade SA
According to Wall Street analysts, the average 1-year price target for ICAD is 21.61 EUR with a low forecast of 16.46 EUR and a high forecast of 35.07 EUR.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is ICAD's stock price target?
Price Target
21.61
EUR
According to Wall Street analysts, the average 1-year price target for ICAD is 21.61 EUR with a low forecast of 16.46 EUR and a high forecast of 35.07 EUR.
What is the Revenue forecast for Icade SA?
Projected CAGR
-39%
Over the last 14 years, the compound annual growth rate for Revenue has been 0%. The projected CAGR for the next 3 years is -39%.
What is the Operating Income forecast for Icade SA?
Projected CAGR
4%
Over the last 14 years, the compound annual growth rate for Operating Income has been 2%. The projected CAGR for the next 3 years is 4%.
